Introductory Chapter: Muscular Dystrophy and Potential Therapeutic Alternatives
Reference14 articles.
1. Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687-695 [Internet] Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673602078157
2. Gianola S, Castellini G, Pecoraro V, Monticone M, Banfi G, Moja L. Effect of Muscular Exercise on Patients with Muscular Dystrophy: A Systematic Review and Meta-Analysis of the Literature. Front Neurol. Nov 12 2020;11:958. doi: 10.3389/fneur.2020.00958
3. Guiraud S, Davies KE. Pharmacological advances for treatment in Duchenne muscular dystrophy. Current Opinion in Pharmacology. 2017;34:36-48 [Internet] Available from: https://linkinghub.elsevier.com/retrieve/pii/S147148921630100X
4. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen G-J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation. 2009;30(3):293-299 [Internet] Available from: https://onlinelibrary.wiley.com/doi/10.1002/humu.20918
5. Mercuri E, Bönnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394(10213):2025-2038 [Internet] Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619329101